PolyPid Ltd. (NASDAQ:PYPD) Receives $12.25 Average Price Target from Brokerages

PolyPid Ltd. (NASDAQ:PYPD) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $12.25.

Several equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Wednesday, February 11th. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of PolyPid in a research report on Monday, December 29th.

Institutional Investors Weigh In On PolyPid

Several institutional investors have recently added to or reduced their stakes in PYPD. BNP Paribas Financial Markets boosted its position in PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after buying an additional 3,500 shares during the period. AIGH Capital Management LLC boosted its position in PolyPid by 26.1% during the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock valued at $5,828,000 after buying an additional 277,844 shares during the period. HighTower Advisors LLC purchased a new stake in shares of PolyPid in the 4th quarter worth about $44,000. Jane Street Group LLC purchased a new stake in shares of PolyPid in the 4th quarter worth about $66,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of PolyPid in the 4th quarter worth about $451,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Stock Performance

PYPD stock opened at $4.74 on Monday. PolyPid has a 52 week low of $2.44 and a 52 week high of $5.12. The firm’s fifty day moving average is $4.34 and its 200 day moving average is $4.09. The firm has a market cap of $90.44 million, a P/E ratio of -2.10 and a beta of 1.45.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.07). As a group, analysts forecast that PolyPid will post -1.79 EPS for the current year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.